PRO/AH/EDR> Ebola update (03): Ebanga monoclonal antibody

Ebola — Worldwide/Unknown
Biotechnology company, Ridgeback Biotherapeutics, announced recently that the U.S. Food and Drug Administration (FDA) approved EbangaTM for the treatment of Ebola.
Ebanga is now approved for treatment of infection caused by _Zaire ebolavirus_ in adult and pediatric patients (including neonates born to a mother who is RT-PCR positive for _Zaire ebolavirus_ infection).
Ebanga is the only FDA approved, single injection Ebola treatment which is available in a lyophilized form.
Ebanga